EUVIMEDEUVIMED entdecken
Crossref

Treatment of posttraumatic headache migraine phenotype with erenumab – An observational study

James A Charles

Journal of Concussion · 2019

DOI: 10.1177/2059700219878292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Concussion, 2019. Verfasst von James A Charles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To report the observed effect of erenumab in mild posttraumatic headache migraine phenotype with and without aura.

Background

There is no clinical algorithm of pharmacotherapy for migraine following posttraumatic headache. Most migraine preventatives that are typically used are either ineffective or not tolerated.

Methods

Seven patients who met the clinical criteria for migraine with or without aura following posttraumatic headache who failed or were intolerant of conventional migraine preventatives were treated with erenumab 140 mg subcutaneously. Most had no history of migraine. In those patients with a history of migraine, the posttraumatic headache migraine headaches were different than the past migraine experience. Descriptive headache intensity or disability using the Head Impact Test-6 and monthly headache days were recorded before and after treatment. All patients were debilitated on presentation and demonstrated no signs of spontaneous resolution.

Results

Patients responded with a 95% (SD 1.22, p < .001) reduction in headache days. All Head Impact Test-6 scores went from disabling to non-disabling without adverse effects. Most required only one dose of erenumab with no migraine recurrence. Onset of efficacy often became apparent within days to four weeks. Extended follow-up six months after treatment revealed no relapses.

Conclusions

Erenumab is effective in the treatment of posttraumatic headache with migraine phenotype in this small cohort. Large-scale studies are urgently required for this highly prevalent, disabling, condition which has no effective established treatment.

Zitieren

APA

Charles, J. A. (2019). Treatment of posttraumatic headache migraine phenotype with erenumab – An observational study. Journal of Concussion. https://doi.org/10.1177/2059700219878292

Vancouver

Charles JA. Treatment of posttraumatic headache migraine phenotype with erenumab – An observational study. Journal of Concussion. 2019. doi:10.1177/2059700219878292

BibTeX
@article{Charles2019,
  author = {Charles, James A},
  title = {Treatment of posttraumatic headache migraine phenotype with erenumab – An observational study},
  journal = {Journal of Concussion},
  year = {2019},
  doi = {10.1177/2059700219878292}
}
Kostenlos starten →